Our solid orals portfolio comprises of immediate release & complex modified release formulations.

• 5 Solid Orals launched in US & 25 Solid Orals under development or ongoing Pilot/Pivotal bioequivalence studies. These are marketed through our US affiliate Indicus Pharma.
• 4 Solid Orals launched in Europe and 10 solid oral dossiers are on offer for EU market. 15 solid orals under development or ongoing Pilot/Pivotal bioeqivalence studies.

These are manufactured at our cGMP compliant plants in India which are ISO 14001 and OHSAS 18001 certified.

For more information about our existing portfolio and our pipeline products please e-mail us.